Baltimore, Maryland-based View Systems provides state-of-the-art security technology products for the growing $100 billion a year security industry. The company’s solutions are applicable for a wide range of entities in need of security solutions, including correctional institutions, government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

ViewScan, the company’s flagship product, is an advanced walk-through Concealed Weapons Detection System (CWD) that utilizes highly sensitive, completely passive sensor technology that drastically simplifies the process of discriminating suspicious items from harmless ones. The technology accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles.

While highly accurate, the system does not emit electro-magnetic fields, radiation, millimeter waves or X-rays, which means it’s safe for pacemakers, implants and pregnant women. In addition, ViewScan has been designated by the U.S Department of Homeland Security as a Qualified Anti-Terrorism Technology (QATT).

Due to a high demand from the correctional industry, View Systems added the LAW Handheld Metal Detector to its Weapon Detection Devices product line. The company’s NEW Law is a high-sensitivity metal detector that features rapid speed and high definition technology that makes it highly complementary to the ViewScan.

View Systems’ first response remote video transmission system is utilized in areas where hazardous materials have been exposed. The solution is small enough to be worn on a belt, helmet or vest, and it transmits conventional video or infrared imagery to the command post, making it ideal for law enforcement SWAT teams, Fire Rescue units and HAZMAT team operations.

The company is constantly conducting research and development to ensure its technologies evolve with the changing security environment. Leading this charge is a senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board

Milestone Scientific, Inc. (NYSE MKT: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Since 1995, the company’s commitment to advancing the science of computer-controlled drug delivery technologies has helped it earn global distinction as an industry leader in the fields of medicine and dentistry. Milestone’s patented CompuFlo® system and DPS Dynamic Pressure Sensing® technology are revolutionary tools that enable practitioners to accomplish a collection of tasks that exceed the capabilities of the 150 year-old manual syringe.

The CompuFlo® system provides a safer, painless delivery alternative for all types of subcutaneous injections in the medical practice. Utilizing Milestone’s proprietary pressure sensing technology, the system offers safe, effective feedback to assist healthcare providers in identifying a specific anatomic location. In addition to more accurate injections, the platform is capable of documenting injection events to provide more reliable recordkeeping for both patients and healthcare providers.

In recent months, Milestone, through its Epidural & IA subsidiary, has turned its attention towards a clinical trial to verify the placement of the epidural needle tip in the lumbar epidural space. Since receiving FDA approval in March, the company has opened enrollment for clinical testing, aiming to enroll up to 400 patients in the trial at four sites throughout the United States.

“A major focus of the Company in 2015 is commercializing the first medical applications of our technology platform, including those licensed by our Epidural & IA Subsidiary,” stated Leonard Osser, Chief Executive Officer of Milestone. “Our Epidural & IA Subsidiary has been in negotiations with distributors in a number of countries… [and] recently signed its first distribution agreement with TRIMED SP.z.o.o., one of the largest distributors of diagnostic equipment in Poland.”

In the first quarter of 2015, Milestone made took major steps towards realizing sustainable growth by signing a letter of intent with MILA International for marketing, distribution and commercialization of an anesthetic delivery instrument for maxillary nerve block procedures in horses. Through this agreement, the company will gain access to the $24 billion global animal health industry, providing an additional platform for continued expansion.

“Our strategy is to collaborate on the development, commercialization and distribution of an anesthetic delivery instrument… [for which] MILA will be responsible for marketing and distribution and Milestone will manufacture product,” continued Osser.

For prospective investors, the company’s continued dedication to innovation and an increasingly broad collection of target markets provide the opportunity to realize sustainable returns in the future.

For more information, visit www.milesci.com

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) is an oil and gas Exploration and Production company with a primary focus on acquisition and development of highly profitable domestic oil fields. Based in Plano, Texas, the company currently holds interests in Texas, Kansas and Oklahoma, providing access to established plays including the Eagle Ford, Mississippian and Hunton. Torchlight’s focus on highly probable and profitable drilling and working interest programs that feature proven and bookable reserves has allowed the company to strategically position itself for tremendous growth moving forward.

Among Torchlight’s most promising projects is the Hunton Play, which is located in Logan and Kingfisher Counties, Oklahoma. The company’s interest in the area is divided into two unique projects: The Cimarron Project and The Chisholm Trail Project, of which Torchlight owns a 15 percent and 15.3 percent working interest, respectively. Combined, the two nearly contiguous projects cover an area of approximately 8,800 acres and fit well into the company’s strategic plan of leveraging new technologies to capitalize on established plays.

In September 2014, Torchlight acquired a 100 percent working interest in its 172,000 acre Orogrande Basin prospect. Through this agreement, the company received a five-year lease on the property that also carries additional five-year extension provisions. In March, Torchlight took a major step towards capitalizing on this interest by beginning drilling operations on its first well on the property. In May, the company built on this progress through the announcement that it had reached total depth on its initial test well.

“We are encouraged by the prospect that this well provides Torchlight shareholders,” stated Will McAndrew, Chief Operating Officer of Torchlight. “Although early in the process, we are very encouraged by what we have encountered while drilling.”

In recent weeks, Torchlight has turned its attention towards investment in order to gain the flexibility required to maximize the value of its current projects. Earlier this week, the company announced that it had closed on the sale of nearly $10 million in Series A Convertible Preferred Stock. This move allowed the company to pay off its senior debt and prepare for continued growth into the future.

“We are thrilled to get this transaction completed with favorable terms and in the current market environment,” stated John Brda, Chief Executive Officer of Torchlight. “This new capital allows us to fulfill the commitments made to our stakeholders and further the development of our asset base.”

For prospective investors, Torchlight’s recent moves have made it an intriguing option in the coming months. As the company continues to develop its Orogrande Project and expand its production capabilities, Torchlight could be in a strong position to realize sustainable returns for the foreseeable future.

For more information, visit www.torchlightenergy.com

Transition Therapeutics, Inc. (NASDAQ: TTHI) is a biopharmaceutical company developing novel therapeutics for disease indications with large markets. The company’s leading drug candidate, ELND005, is designed to treat the agitation and aggression associated with Alzheimer’s disease and Down syndrome. Additionally, Transition is developing TT401, a metabolic drug candidate formulated to treat type 2 diabetes and its accompanying obesity. Through the continued development and clinical testing of these two products, the company is addressing medical markets that are currently underserved.

According to the Alzheimer’s Association, an estimated 5.3 million Americans of all ages currently suffer from Alzheimer’s disease. Among those individuals, up to 60 percent will develop behavioral symptoms, such as agitation or aggression, over the course of their lives. Transition is making progress towards improving the comfort of those affected by these symptoms through the continued development of ELND005. In a completed Phase II study, the drug candidate appeared to decrease the emergence and severity of these neuropsychiatric symptoms by reducing myo-inositol levels in the brain.

In March, Transition took a major step towards the commercialization of its leading drug candidate through the completion of absorption-metabolism-excretion (AME) and renal clearance studies. These trials are required by the United States Food and Drug Administration for the approval of nearly all drugs in development. In both cases, ELND005 demonstrated good safety and tolerability, clearing the path for more advanced clinical trials moving forward.

The company’s product pipeline was expanded in May when Transition announced that its wholly-owned subsidiary had acquired exclusive worldwide licensing rights to TT701, a selective androgen receptor modulator that’s been shown to significantly increase lean body mass and muscle strength in male subjects.

“The safety and efficacy profile of TT701 creates a number of development opportunities,” stated Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition. “[The company] will initiate development and manufacturing activities to enable the start of a Phase 2 study in the coming months.”

Transition is expected to continue making progress towards the commercialization of its robust product pipeline moving forward. With Phase II clinical trials for three drug candidates in four unique indications ongoing, completed or upcoming, the company appears to be closing in on a significant opportunity to realize sustainable returns in the years to come.

For more information, visit www.transitiontherapeutics.com

Pure Hospitality Solutions, Inc. (OTC: PNOW) announced that it had teamed with Costa Rica-based Jaco Tour Company, allowing the company’s upcoming OTA, the Oveedia Travel Network, to officially add excursions to its growing database of reservation options.

“Today marks another major milestone for PURE, Oveedia and our reputation within the Central American-Caribbean region,” stated Melvin Pereira, President and Chief Executive Officer of Pure. “After a number of conversations and meetings, Oveedia has its first independent tour company, on-top of Sabre’s extensive database.”

Through the deal, Pure has agreed to feature the Jaco Tour Company on Oveedia’s homepage, providing travelers with access to exclusive pricing on fishing charters, transportation, local tours and day trips throughout all of Costa Rica. Moving forward, these independent offers will allow Pure to differentiate Oveedia from worldwide OTAs, further demonstrating the market for region-specific solutions in the Central American-Caribbean travel market and, potentially, increasing the end value of the Oveedia platform.

“While being a part of Sabre’s $7 Billion Travel Network family is absolutely crucial, it’s the independent hotels and companies, such as the Tango Mar and now the Jaco Tour Company, which makes Oveedia completely unique and extremely valuable,” continued Pereira. “Oveedia will have an entire region of properties and travel companies represented on its platform that are not readily listed on larger, globally known OTA’s. This, in and of itself, makes the platform extremely valuable as an acquisition target.”

Earlier this week, Pure took a major step towards the launch of its groundbreaking OTA platform by submitting the Oveedia architecture to the Sabre Travel Network. Through its partnership with Sabre, the company added more than 125,000 hotels, 400 airlines, 16 cruise lines and 25 car rental selections to its reservation database, but the importance of independent deals to the overall success of Oveedia can’t be overstated. With the early stages of the company’s three phase rollout of the network scheduled to begin in the upcoming weeks, Pure is continuing to amplify the OTAs massive potential through these region-specific partnerships.

According to a report by eMarketer, the Latin American region has led the world in terms of online travel sales growth for the better part of a decade. From 2010 to 2013, the region recorded annual growth topping 30 percent, and this rapid expansion is expected to continue in the years to come. Through the development of the Oveedia platform, Pure is positioning itself to translate this growth into sustainable returns moving forward. Look for the company to make waves in the OTA industry as it continues to expand its database of booking options, establishing Oveedia as a potentially lucrative acquisition target in the near future.

For more information on Pure Hospitality Solutions, visit www.purenow.solutions

Let us hear your thoughts: Oriens Travel and Hotel Management Corp. Message Board

Los Angeles-based MIT Holding has an established working arrangement with one of the approximately 400 compounding licensed pharmacies remaining in the United States. Currently, many big name pharmaceutical companies are buying up these compounding pharmacies to eliminate competition. However, MIT Holding has a contractual arrangement with a well-respected and highly qualified compounding pharmacy that enables it to fulfill its own infusion and other specialty prescriptions. This capability provides MIT Holding with a distinct advantage over local “mom-and-pop” infusion centers in the rapidly growing $11 billion a year U.S. infusion therapy market.

The two most recognized names in the infusion sector are CVS Health Corp. (NYSE: CVS) and Walgreen Co. (NYSE: WAG). Both of which have established footprints into the home infusion market through a series of strategic acquisitions that highlight the growing demand for home infusion services.

CVS earlier this year completed its acquisition of Coram LLC, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc., and in May entered into a definitive agreement to acquire Omnicare (NYSE: OCR). The acquisition of Omnicare is expected to greatly expand CVS’s specialty pharmacy business and increase its ability to dispense prescriptions in assisted living and long-term care facilities.

MIT Holding is also uniquely positioned to opportunities in the prescription dispensary and in-home infusion services markets. That is because MIT Holding’s business model is built around the company’s full suite of in-home recovery services, which begins when MIT Holding sends a company representative to a patient’s hospital bed on the day of discharge to establish a blueprint for successful home recovery.

Following the initial contact, MIT Holding will send a registered nurse (RN) directly to the patient’s home to provide infusion therapies and consultation. The typical four-hour infusion procedure allows the RN to establish a personal working rapport and customized recovery regimen for the patient, while cross-marketing MIT Holding’s complete suite of services. The RN offers a thorough analysis of the patient’s needs, from medications, durable medical equipment, doctor appointments, therapy sessions, insurance billing, insurance inquires, and a financial overview of the expected expenses of the remaining recovery period.

With current MIT Holding patients, this cross marketing approach is effective by including all other household members. MIT Holding benefits with an immediate expansion of its patient base by offering its services to meet the medical needs of these family members. Results have shown that families and patients often realize valuable savings on their medications, including the original infusion therapies.

MIT Holding’s new approach establishes a digital databank of information on the patient’s recovery regimen, which was created at the bedside of the patient at the point of discharge. This creates a new revenue stream of vital records necessary for doctors and hospitals to comply with new mandatory federal requirements, documenting their patient’s recovery.

Through its innovative and comprehensive in-home recovery services, which include specialty drugs, infusion services, compounding pharmaceuticals, direct insurance inquiries, insurance billing, and cross marketing efforts, MIT Holdings is in prime position to take advantage of multi-billion dollar markets. Based on IMS Health data, the specialty pharmaceuticals market is valued at $77.5 billion, constituting roughly a quarter of the overall market and growing at more than double (8.8%) the rate. Combined with the $11 billion home infusion market, these sectors are rapidly approaching the $100 billion mark.

For more information visit www.mitholding.com or contact William Nalley at 305-515-8077

Let us hear your thoughts: MIT Holding, Inc. Message Board

InvenSense, Inc. (NYSE: INVN) is the world’s leading provider of intelligent sensor system on chip (SoC) for Motion and Sound solutions in consumer electronic devices – including smartphones, tablets, wearables, gaming devices, optical image stabilization and remote controls for Smart TVs. The company’s patented InvenSense Fabrication Platform and patent-pending MotionFusion™ technology address the emerging needs of many mass-market consumer applications via improved performance, accuracy, and intuitive motion-, gesture- and sound-based interfaces.

Beginning with the world’s first dual-axis MEMS gyroscopes for the digital still camera market in 2006, InvenSense has developed a reputation for innovation within the industry by consistently delivering game changing solutions. In 2009, the company released the first integrated 3-axis motion processing solution for smartphones, and, in 2010, it unveiled the world’s first single-chip integrated 6-axis MotionTracking™ device. Among the company’s latest solutions is the ICM-20728, which was recognized as the world’s first integrated 7-axis single-chip platform solution with onboard Digital Motion Processor (DMP™) upon its release in 2014. By remaining on the cutting-edge of the industry, InvenSense is in a formidable position to realize continued growth moving forward.

In March, the company continued to expand its industry presence through the announced availability of its InvenSense Positioning Library (IPL) software, which is designed to provide sensor assisted positioning in places where GPS accuracy isn’t adequate. This announcement further demonstrated the potentially massive reach of the company’s expansive product line.

“With more consumers using their smartphones for turn-by-turn navigation on foot or in vehicle, one of the most frustrating user experience issues is losing your GPS signal in an unfamiliar location or being re-routed erroneously due to multipath errors,” stated Ali Foughi, Vice President of Marketing and Business Development at InvenSense. “With IPL technology, high accuracy location guidance is always available and provides Smartphone OEMs with a differentiated user experience and consumers with a more reliable navigation solution.”

Through continued innovation and the release of a number of new products, InvenSense realized dramatic financial growth in recent months. In the fourth quarter of fiscal year 2015, InvenSense recorded a 68 percent increase in year-over-year net revenue, securing a 47 percent boost in annual net revenue, as compared to fiscal year 2014.

“Fiscal 2015 was a significant year for InvenSense,” stated Behrooz Abdi, President and Chief Executive Officer of InvenSense. “We achieved the highest revenue in company history, driven by strong market share gains and several high-volume customer wins… Our success in mobile in fiscal 2015 laid important groundwork for our continued achievement in the coming year.”

In the months to come, look for InvenSense to continue to build on its established industry presence through a dedication to unrelenting innovation and strategic growth into potentially lucrative new verticals. For prospective investors, the company’s strong financial results could clear the way for sustainable returns into the future.

For more information, visit www.invensense.com

When Stacey McBride-Irby, creator of The Prettie Girls! recently commented, “A happy, inspired childhood creates happy, inspired and powerful women,” she was putting her passion for One World Holdings, Inc. (OTC: OWOO) mission front and center on the national toy market stage. And when your company’s Chief Product Development Officer is that ‘out front’ with their feelings about the task at hand, shareholders can rest assured they have the right person for the job.

Before McBride-Irby’s tenure as the Chief Product Development Officer at OWOO, she established her talent credentials in the toy industry during her 15 years as a Project Designer for Mattel™. Since then, she has helped put The One World Doll Project on the map through her diverse collection of doll designs.

Evidence of the company’s drive to meet the needs of a diverse doll market demographic, the company announced an initial order from Amazon, adding to a burgeoning retail network that includes industry giants such as Toys ‘R’ Us and Sears. In a recent conference call, the agreement was characterized as just the first step of One World’s upcoming expansion plans. Timing could not be better as the company aims to boost its retail presence in preparation for the 2015 holiday shopping season.

Trey Waldhauser, Vice President of Business Development at One World, noted, “As we continue to see a significant increase in product sales, this new business relationship with Amazon.com represents another component of our 2015 growth plan. It’s extremely motivating to see the world’s largest online retailer take an interest in our products.”

The company’s momentum into the retail space is providing OWOO a stable foundation for generating and expanding its revenue base. At the beginning of the current quarter, the company announced a 532 percent increase in year-over-year revenue for 2014 while its national expansion puts One World in a strategically desirable position to build on this growth going forward.

Toy Association research indicates the domestic toy market has been expanding in recent years with 4% increase in market value in 2014. Last year, dolls accounted for $2.32 billion in the United States, and market indicators point to continued growth for 2015.

For more information on the company visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

In the U.S. alone each year, roughly 150k people develop some form of the seizure spectrum disorder known as epilepsy, which is the fourth most common neurological disorder known to man and which is characterized by not only unpredictable seizures, but other health problems as well, like increased risk of heart disease and stroke. With some 50 million people currently afflicted with epilepsy worldwide and the current standards of care producing a variety of side effects in up to 90 percent of patients, as many as 25 percent of all patients discontinue treatment due to experiencing adverse side effects (many others simply try to cope). Side effects which range from mood changes, abrupt stoppage-related seizure frequency increases and liver toxicity, to decreased bone marrow function, and even birth defects. A staggering one out of every twenty six people will develop epilepsy at some point in their lives, but the highest incident rates are among the elderly and the very young, with over 466k children diagnosed here in the U.S., and over 765k in Europe, according to AAP data published in Pediatrics back in 2012.

Severe seizures lasting longer than five minutes (status epilepticus), SUDEP (sudden unexpected death in epilepsy, which accounts for 34 percent of deaths in children with epilepsy) and the often-associated social and developmental problems which tragically lead to an inordinately high incident rate of suicides among epilepsy sufferers mean that patients with epilepsy have a statistically increased risk of death compared to the general population, which ranges from 1.6 times higher (low end of SE/SUDEP), up to as much as 6 times higher (high end of suicide rate). Thankfully, the emerging clinical understanding of the key role that the human endogenous cannabinoid system (endocannabinoids) plays in regulating a wide variety of physiological processes has led to paradigm-shattering advances in recent years that may soon do away with the current generation of epilepsy drugs like carbamazepine, phenytoin, valproate (the one most clearly linked to birth defects), and the barbiturate known as phenobarbital.

One of the companies at the forefront of cannabinoid science today, which specializes in pioneering the kind of cutting-edge research that leads not only to new clinical data on the pharmacokinetics of plant-based cannabinoids (phytocannabinoids) like CBD (the non-psychoactive component of the cannabis sativa plant, known as cannabidiol) and THC (the psychoactive component, delta-9-tetrahydrocannabinol), but powerful new IP for the creation of market-defining therapies, is London-based GW Pharmaceuticals (NASDAQ: GWPH) (LSE: GWP). The company’s growing understanding of the importance of the human body’s currently identified (there may be more) cannabinoid receptors CB1 and CB2, respectively found in neurological tissues, as well as glands (CB1), and in immune system tissues (CB2), has led to an impressive product pipeline that has managed to not only garner significant attention from the medical community, but also seriously impress industry regulators like the FDA.

The ability of CBD and THC to act as neuroprotectant antioxidants, helping to secure vital brain function in the face of degenerative diseases, as well as severe injuries and stroke, is paramount when it comes to understanding the neuromodulatory potential of cannabinoid therapies. And the more recent evidence that cannabinoids have broad-spectrum potential in anti-inflammatory, pain relief and immunomodulatory applications should give investors the kind of over-the-horizon radar needed to understand the upper limits for a company like GWPH, whose proprietary cannabinoid development platform is really just getting warmed up.

The company’s lead candidate Epidiolex® has seen barriers for its application in Dravet and Lennox-Gastaut syndromes, two cripplingly severe forms of epilepsy, melt away in recent years. With FDA Fast Track granted to Epidiolex in Dravet syndrome and pivotal Phase 3 studies now engaged in for both Dravet and Lennox-Gastaut, broader application in general epilepsy (currently in Phase 2) looks solid. The entry into Phase 2 clinical trials of cannabidivarin (CBDV) in adult patients with epilepsy last month shows how far-reaching the company’s next-gen epilepsy therapy platform really is. If the pre-clinical safety and efficacy data is any indication, with CBDV having been well tolerated at even maximum dosages, with no side effects or withdrawals, CBDV could soon be stealing even Epidiolex’s thunder.

Hence the recent move of the company’s CEO, Justin Gover, to the U.S., as well as the appointment of Julian Gangolli, whose distinguished career at specialty pharma giant Allergan speaks for itself, to the role of President of the company’s North America operations. The company is now eagerly setting up shop in SoCal and looks forward to the possible commercial launch of Epidiolex, for which the most recent physician reports out in April, referring to its use in children and young adults with treatment-resistant forms of epilepsy, look extremely promising. GWPH is banking on big things in North America for the future of their pipeline, and has struck hard and fast ahead of the curve in order to establish a firm commercial infrastructure footprint here well before they clear Phase 3, in order to maximize profitability when the time comes.

With median seizure reduction after a 12-week run of around 54 percent in reported from the company’s expanded access program and a clear ability to maintain clinical effect all the way in at the 24 week mark, as well as a 90 percent patient retention, in whom Epidiolex was found to be well tolerated, GW Pharmaceuticals is now confidently gearing up to aggress further pediatric epilepsy targets like TSC (Tuberous Sclerosis Complex). Having kicked off Phase 3 clinical trials in Lennox-Gastaut syndrome (LGS) last month, subsequent to the reception of Orphan Drug Designation from the FDA, GW Pharmaceuticals is roaring towards an NDA as early as 2016 for Epidiolex in LGS, which continues to be one of the most drug-resistant and difficult to treat forms of epilepsy, and usually starts before the age of four in afflicted children.

The importance of a safe, well-tolerated therapy derived from plants, like the purified and formulated CBD indication Epidiolex, is absolutely essential for treating children who are diagnosed as being at risk for epilepsy, as no parent wants to start their young child out on a lifelong commitment to taking potentially dangerous synthetic pharmaceuticals like those mentioned earlier. The ability to make a comfortable decision with something like Epidiolex, secure in the knowledge that the seizures can be treated without causing the kinds of long-term side effects like those seen with other epilepsy drugs, is a factor that could make Epidiolex far more than a massive revenue generation engine for GWPH – it could make Epidiolex into a meaningfully capable new standard of care.

Moreover, unlike the company’s other top cannabis-based candidate, the oral spray Sativex® – which is approved in Europe for multiple sclerosis-related spasticity and which is being worked up as a cancer pain indication with applicability in other types of pain – Epidiolex is not licensed to majors like Bayer, Novartis, and Otsuka Pharmaceutical. This key fact puts GWPH in the pole position when it comes to capitalizing on the commercialization of Epidiolex, and it should be of particular note to savvy investors.

Take a closer look by visiting www.gwpharm.com

The MaryJane Group, Inc. (OTCQB: MJMJ), the innovative company behind Colorado’s popular Bud+Breakfast™ lodges, debuted the latest addition to its collection of cannabis-centric hospitality destinations on Tuesday, and it’s like nothing else in the industry. CannaCamp combines recreational marijuana use and education with a traditional ranch experience to create the country’s first and only cannabis resort. Located on a 172-acre dude ranch near Durango, Colorado, CannaCamp provides guests with a near limitless supply of outdoor entertainment and a personal cannabis concierge to ensure that they’ve always got the perfect strain to pair with specific activities and meals.

“There is truly no place like this in the entire world,” stated Joel Schneider, Chief Executive Officer of The MaryJane Group. “We’re bringing an element of luxury to that adventurous, exploratory vibe of childhood summer camp – in a beautiful setting where visitors can enjoy marijuana in a safe, comfortable, social environment.”

Moving forward, CannaCamp will join The MaryJane Group’s two existing Bud+Breakfast™ lodges, providing the company with ample opportunity to realize significant returns in the months to come. In April, the company announced that it had already booked over $300,000 in new reservations for its two original properties, putting it on pace to achieve one of the highest occupancy rates in the entire state of Colorado, and The MaryJane Group is in a strong position to build on this progress as it begins accepting reservations for CannaCamp’s inaugural summer season.

Since being legalized for recreational use in 2014, the Colorado cannabis industry has exceeded expectations in terms of overall sales. In 2014, combined sales of recreational and medical marijuana accounted for $699 million throughout the state, outpacing early estimates by the Legislative Council of the Colorado General Assembly by more than 20 percent. These results demonstrated the overall marketability of both recreational cannabis and its related verticals.

For The MaryJane Group, the announcement of another groundbreaking property puts the company in a great position to continue building brand recognition throughout both the state and the country. Expanding on the early successes of its inventive hospitality platform, the company should be in a formidable position to continue to thrive as the preeminent hospitality group in the marijuana industry through a healthy balance of innovation and strategic growth.

For more information, visit www.themaryjanegrp.com